Effect of Low-Dose, long-Term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Liu, Jifeng ^a   Zhong, Xiaoning ^a   He, Zhiyi ^a   Wei, Lianghong ^b   Zheng, Xiaozhen ^b   Zhang, Jianquan ^a   Bai, Jing ^a   Zhong, Wei ^b   Zhong, Dengjun ^b  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; HYALURONIDASE; INTERLEUKIN 8; LEUKOCYTE ELASTASE; MATRIX METALLOPROTEINASE; ROXITHROMYCIN; ANTIINFECTIVE AGENT; COLLAGEN TYPE 4; HYALURONOGLUCOSAMINIDASE; IL8 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN;

ADULT; AIRWAY REMODELING; ARTICLE; BRONCHIECTASIS; CHINESE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; FEMALE; HUMAN; IMAGING SOFTWARE; LONG TERM CARE; LOW DRUG DOSE; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFLAMMATION; SPUTUM ANALYSIS; STEADY STATE; TREATMENT DURATION; ADOLESCENT; AGED; BRONCHUS; CHEMISTRY; INFLAMMATION; METABOLISM; MIDDLE AGED; NEUTROPHIL; QUALITY OF LIFE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BRONCHI; COLLAGEN TYPE IV; FEMALE; HUMANS; HYALURONOGLUCOSAMINIDASE; INFLAMMATION; INTERLEUKIN-8; LEUKOCYTE ELASTASE; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEUTROPHILS; QUALITY OF LIFE; ROXITHROMYCIN; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84949000441     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/708608     Document Type: Article

References (33)

1. A. E. O'Donnell, "Bronchiectasis, " Chest, vol. 134, no. 4, pp. 815- 823, 2008.
2. P. T. King, "The pathophysiology of bronchiectasis, " International Journal of Chronic Obstructive Pulmonary Disease, vol. 4, pp. 411-419, 2009.
3. D. A. Bergin, K. Hurley, A. Mehta et al., "Airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis, " Journal of Inflammation Research, vol. 6, no. 1, pp. 1-11, 2013.
4. P. King, "Pathogenesis of bronchiectasis, " Paediatric Respiratory Reviews, vol. 12, no. 2, pp. 104-110, 2011.
5. M. Baydarian and R. N. Walter, "Bronchiectasis: introduction, etiology, and clinical features, " Disease-A-Month, vol. 54, no. 8, pp. 516-526, 2008.
6. S. Fuschillo, A. De Felice, and G. Balzano, "Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms, " European Respiratory Journal, vol. 31, no. 2, pp. 396-406, 2008.
7. A. L. Friedlander and R. K. Albert, "Chronic macrolide therapy in inflammatory airways diseases, " Chest, vol. 138, no. 5, pp. 1202-1212, 2010.
8. K.-I. Kanai, K. Asano, T. Hisamitsu, and H. Suzaki, "Suppression of matrix metalloproteinase-9 production from neutrophils by a macrolide antibiotic, roxithromycin, in vitro, " Mediators of Inflammation, vol. 13, no. 5-6, pp. 313-319, 2004.
9. J. Ilowite, P. Spiegler, and S. Chawla, "Bronchiectasis: new findings in the pathogenesis and treatment of this disease, " Current Opinion in Infectious Diseases, vol. 21, no. 2, pp. 163-167, 2008.
10. A. T. Hill, M. Pasteur, C. Cornford, S. Welham, and D. Bilton, "Primary care summary of the BritishThoracic Society Guideline on the management of non-cystic fibrosis bronchiectasis, " Primary Care Respiratory Journal, vol. 20, no. 2, pp. 135-140, 2011.
11. J.-F. Liu, X.-N. Zhong, Z.-Y. He et al., "Impact of treatment with low dose roxithromycin on stable bronchiectasis, " Zhonghua Jie He He Hu Xi Za Zhi, vol. 35, no. 11, pp. 824-827, 2012.
12. A. E. O'Donnell, A. F. Barker, J. S. Ilowite, and R. B. Fick, "Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I, " Chest, vol. 113, no. 5, pp. 1329-1334, 1998.
13. E. P. Judge, J. D. Dodd, J. B. Masterson, and C. G. Gallagher, "Pulmonary abnormalities on high-resolution CT demonstrated more rapid decline than FEV1 in adults with cystic fibrosis, " Chest, vol. 130, no. 5, pp. 1424-1432, 2006.
14. E. Pizzichini, M.M.M. Pizzichini, A. Efthimiadis et al., "Indices of airway inflammation in induced sputum: Reproducibility and validity of cell and fluid-phase measurements, " The American Journal of Respiratory and Critical CareMedicine, vol. 154, no. 2, part 1, pp. 308-317, 1996.
15. R. D. Gray, G. MacGregor, D. Noble et al., "Sputumproteomics in inflammatory and suppurative respiratory diseases, " The American Journal of Respiratory and Critical CareMedicine, vol. 178, no. 5, pp. 444-452, 2008.
16. A. Pye, R. A. Stockley, and S. L. Hill, "Simple method for quantifying viable bacterial numbers in sputum, " Journal of Clinical Pathology, vol. 48, no. 8, pp. 719-724, 1995.
17. G. C. Ooi, P. L. Khong, M. Chan-Yeung et al., "High-resolution CT quantification of bronchiectasis: clinical and functional correlation, " Radiology, vol. 225, no. 3, pp. 663-672, 2002.
18. S.A. Little, M. W. Sproule, M. D. Cowan et al., "High resolution computed tomographic assessment of airway wall thickness in chronic asthma: Reproducibility and relationship with lung function and severity, " Thorax, vol. 57, no. 3, pp. 247-253, 2002.
19. K. Kasahara, K. Shiba, T. Ozawa, K. Okuda, and M. Adachi, "Correlation between the bronchial subepithelial layer and whole airway wall thickness in patients with asthma, " Thorax, vol. 57, no. 3, pp. 242-246, 2002.
20. P. W. Jones, F. H. Quirk, C. M. Baveystock, and P. Littlejohns, "A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire, " The American Review of Respiratory Disease, vol. 145, no. 6, pp. 1321-1327, 1992.
21. S. Malhotra-Kumar, C. Lammens, S. Coenen, K. vanHerck, and H. Goossens, "Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: A randomised, double-blind, placebocontrolled study, " The Lancet, vol. 369, no. 9560, pp. 482-490, 2007.
22. Y. Y. Koh, M. H. Lee, Y. H. Sun, K. W. Sung, and J. H. Chae, "Effect of roxithromycin on airway responsiveness in children with bronchiectasis: A double-blind, placebo-controlled study, " European Respiratory Journal, vol. 10, no. 5, pp. 994-999, 1997.
23. D. J. Serisier and M. L. Martin, "Long-Term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations, " Respiratory Medicine, vol. 105, no. 6, pp. 946-949, 2011.
24. C. Wong, L. Jayaram, N. Karalus et al., "Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): A randomised, double-blind, placebo-controlled trial, " The Lancet, vol. 380, no. 9842, pp. 660-667, 2012.
25. J. Altenburg, C. S. de Graaff, Y. Stienstra et al., "Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: The BAT randomized controlled trial, " The Journal of the American Medical Association, vol. 309, no. 12, pp. 1251-1259, 2013.
26. D. J. Serisier, M. L. Martin, M. A. McGuckin et al., "Effect of long-Term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: The BLESS randomized controlled trial, " Journal of theAmerican Medical Association, vol. 309, no. 12, pp. 1260-1267, 2013.
27. P. C. Goeminne, J. Soens, H. Scheers, W. De Wever, and L. Dupont, "Effect of macrolide on lung function and computed tomography (CT) score in non-cystic fibrosis bronchiectasis, " Acta Clinica Belgica, vol. 67, no. 5, pp. 338-346, 2012.
28. L. Zheng, W. K. Lam, G. L. Tipoe et al., "Overexpression of matrix metalloproteinase-8 and -9 in bronchiectatic airways in vivo, " European Respiratory Journal, vol. 20, no. 1, pp. 170-176, 2002.
29. R. Sepper, Y. T. Konttinen, T. Sorsa, and H. Koski, "Gelatinolytic and type IV collagenolytic activity in bronchiectasis, " Chest, vol. 106, no. 4, pp. 1129-1133, 1994.
30. M. A. Martínez-García, J.-J. Soler-Cataluña, M. Perpiñá- Tordera, P. Román-Sánchez, and J. Soriano, "Factors associated with lung function decline in adult patients with stable noncystic fibrosis bronchiectasis, " Chest, vol. 132, no. 5, pp. 1565-1572, 2007.
31. Z.-Y. He, L.-M. Ou, J.-Q. Zhang et al., "Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease, " Respiration, vol. 80, no. 6, pp. 445-452, 2010.
32. K. Kanai, K. Asano, T. Hisamitsu, and H. Suzaki, "Suppresion in matrix metalloproteinase production from nasal fibroblasts by macrolide antibiotics in vitro, " European Respiratory Journal, vol. 23, no. 5, pp. 671-678, 2004.
33. X.-N. Zhong, J. Bai, H.-Z. Shi, C. Wu, G.-R. Liang, and Z.-B. Feng, "An experimental study on airway inflammation and remodeling in a rat model of chronic bronchitis and emphysema, " Chinese Journal of Tuberculosis and Respiratory Diseases, vol. 26, no. 12, pp. 750-755, 2003.